The results showed that the tumor volume of mice treated with the combination of PD-1 monoclonal antibody (mAb) and 2-DG (combo group) was significantly reduced compared with that of the single-drug (PD-1 mAb and 2-DG groups) and control (saline group) groups, showing the best therapeutic efficacy (Fig. 7C, D). This evidence concerns the gene PDCD1 and neoplasm.